Differences between graft-versus-leukemia and graft-versus-host reactivity. I. Interaction of donor immune T cells with tumor and/or host cells

Blood

Volumn 89, Issue 6, 1997, Pages 2189-2202

  Rocha, Marian ^b   Umansky, Victor ^b   Lee, Kyeong Hee ^b   Hacker, Hans Jörg ^b   Benner, Axel ^b   Schirrmacher, Volker ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MONOCLONAL ANTIBODY; SIALOADHESIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER TRANSPLANTATION; CELL INFILTRATION; CELL INTERACTION; CONTROLLED STUDY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; IMMUNOHISTOCHEMISTRY; IRRADIATION; LEUKEMIA; LYMPHOCYTE TRANSFER; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL LINE;

EID: 0030899622     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.6.2189     Document Type: Article

References (50)

1. Greenberg PD: Adoptive T cell therapy for tumors: Mechanisms operative in the recognition and elimination of tumor cells, Adv Immunol 49:281, 1991
2. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Toppalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676, 1988
3. Osband ME, Lavin PT, Babayan RK, Graham S, Lamm DL, Parker B, Sawcyck I, Ross S, Krane RJ: Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal cell carinoma. Lancet 335:994, 1990
4. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R: Antileukemic effect of graft-versus host disease in human recipients of allogeneic marrow grafts. N Engl J Med 300:1068, 1979
5. Goldman JM, Gale RP, Horowitz Biggs JC, Champlin RE, Gluckman JM, Hoffmann RG, Jacobson SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806, 1988
6. Slavin S, Ackerstein A, Weiss L, Nagler A, Reuven O, Naparstek E: Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 10:221, 1992
7. Johnson BD, Drobyski WR, Truitt RL: Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 11:329, 1993
8. Hertenstein B, Wiesneth M, Novotny I, Bunjes D, Stefanic M, Heinze B, Hubner G, Heimpel H, Arnold R: Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after alllogeneic bone marrow transplantation. Transplantation 56:1114, 1993
9. Schirrmacher V, Beckhove P, Krüger A, Rocha M, Umansky , V, Fichtner K-P, Hull WE, Zangemeister-Wittke U, Griesbach A, Jurianz K, von Hoegen P: Effective immune rejection of advanced metastasized cancer. Int J Oncol 6:505, 1995
10. Von Hoegen P, Altevogt P, Schirrmacher V: New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells. Cell Immunol 109:338, 1987
11. Schirrmacher V, von Hoegen P, Griesbach A, Zangemeister-Wittke U: Specific eradication of micrometastases by transfer of tumor immune T-cells from MHC congenic mice. Cancer Immunol Immunother 32:373, 1991
12. Zangemeister-Wittke U, Schirrmacher V: Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: Migration, survival and tumor protectivity of cytotoxic donor cells. Biotherapy 3:319, 1991
13. Festenstein H: Immunogenic and biological aspects of in vitro allotransformation (MLR) in the mouse. Transplant Rev 15:62, 1973
14. Abe R, Hodes R: T cell recognition of minor lymphocyte stimulating (Mls) gene products. Annu Rev Immunol 7:683, 1989
15. Acha-Orbea H, MacDonald HR: Superantigen of mouse mammary tumor virus. Annu Rev Immunol 13:459, 1995
16. a is encoded by the long terminal repeat open reading frame of the mouse mammary tumor provirus Mtv-7. Proc Natl Acad Sci USA 89:5432, 1992
17. Choi Y, Kappler JW, Marrack P: A superantigen encoded in the open reading frame of 3′ long terminal repeat of mouse mammary tumor virus. Nature 350:203, 1991
18. Lee BK, Eicher EM: Segregation patterns of endogenous mouse mammary tumor viruses in live recombinant inbred strain sets. J Virol 64:4568, 1990
19. Schneider R, Lees RK, Pedrazzini T, Zinkernagel RM, Hengartner H, MacDonald HR: Postnatal disappearance of self-reactive (vβ6+) cells from the thymus of Mls-1a mice. J Exp Med 169:2149, 1989
20. Larizza L, Schirrmacher V, Pflüger E: Acquisition of high metastatic capacity after in vitro fusion of a non-metastatic tumor line with a bone-marrow derived macrophage. J Exp Med 160:1579, 1984
21. Benke R, Lang E, Komitowski D, Muto S, Schirrmacher V: Changes in tumor cell adhesiveness affecting speed of dissemination and mode of metastatic growth. Invasion Metastasis 8:159, 1988
22. Fichtner KP, Schirrmacher V, Griesbach A, Hull WE: In vivo 1H-NMR microimaging with respiratory triggering for monitoring adoptive immunotherapy of metastatic mouse lymphoma. Magnet Resonance Med (in press)
23. Krüger A, Umansky V, Rocha M, Hacker HJ, Schirrmacher V, von Hoegen P: Pattern and load of spontaneous liver metastasis dependent on host immune status studied with lacZ transduced lymphoma. Blood 84:3166, 1994
24. Diaiynas DP, Quan ZS, Wall K A, Pierres A, Quintans J, Loken MR, Pierres M, Fitch FW: Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK 1.5: Similarity of L3T4 to the human LEU-3/T4 molecule. J Immunol 131:2445, 1983
25. Ledbetter JA, Herzenberg LA: Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol Rev 47:63, 1979
26. Van den Berg TK, Breve JJ P, Damoiseaux JGMC, Döpp EA, Kelm S, Crocker PR, Dijkstra CD, Kraal G: Sialoadhesin on macrophages: Its identification as a Iymphocyte adhesion molecule. J Exp Med 176:647, 1992
27. Tada N, Kimura S, Hatzfeld A, Hämmerling U: Lym 11: The H-3 region of mouse chomosome 2 controls a new surface allogantigen. Immunogenetics 11:441, 1980
28. Krenacs T, Krenacs L, Bpzoky B, Ivanyi B: Double and triple immunocytochemical labeling at the light microscopic level in histopathology. Histochem J 22:530, 1990
29. Rocha M, Krüger A, Umansky V, von Hoegen P, Naor D, Schirrmacher V: Dynamic expression-changes in vivo of adhesion and costimulatory molecules determine load and pattern of lymphoma liver metastases. Clin Cancer Res 2:811, 1996
30. Umansky V, Beckhove P, Rocha M, Krüger A, Crocker PR, Schirrmacher V: A role for sialoadhesin-positive tissue macrophages in host resistance to lymphoma metastasis in vivo. Immunology 87:303, 1996
31. Von Hoegen P, Altevogt P, Schirrmacher V: New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor specific cytolytic T cells. Cell Immunol 109:338, 1987
32. Schirrmacher V, Schild HJ, Gückel B, von Hoegen P: Tumor specific CTL response requiring interactions of four different cell types and dual recognition of MHC class I and class II restricted tumor antigens. Immunol Cell Biol 71:311, 1992
33. Schreiber KL, Forman J: Effect of graft-versus-host disease on anti-tumor immunity. J Immunol 144:2018, 1990
34. Gluckman E: Influence of conditioning on the outcome of allogeneic bone marrow transplantation. Int J Radiat Oncol Biol Phys 19:1325, 1990
35. Izumi Y, Taniuchi Y, Tsuji T, Smith W, Nakamori S, Fidler IJ, Irimura T: Characterization of human colon carcinoma variant cells selected for sialyl Lex carbohydrate antigen: Liver colonization and adhesion to vascular endothelial cells. Exp Cell Res 216:215, 1995
36. Papiernik M, Pontoux Ch, Golstein P: Non-exclusive Fas control and age dependence of viral superantigen-induced clonal deletion in lupus-prone mice. Eur J Immunol 25:1517, 1995
37. Weber GF, Abromson-Leeman S, Cantor H: A signaling pathway coupled to T cell receptor ligation by MMTV superantigen leading to transient activation and programmed cell death. Immunity 2:363, 1995
38. Igantowicz L, Kappler J, Marrack P: The effects of chronic infection with a super-antigen-producing virus. J Exp Med 175:917, 1992
39. Ferrara J, Guillen FJ, Sleckmann B, Buarkoff SJ, Murphy GF: Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: Histologic analysis and correlation with clinical disease. J Invest Dermatol 86:371, 1986
40. Blatter DD, Crawford JM, Ferrara JLM: Nuclear magnetic resonance of hepatic graft versus host disease in mice. Transplantation 50:1011, 1990
41. Spach C, Motta R: Lymphoid cell proliferation in non-lymphoid organs during graft-versus host reactions (GVHR): I. Lack of correlation between mortality and grafted cell proliferation. Exp Hematol 9:531, 1981
42. Kloosterman TC, Tietmans MJ, Martens AC, van Bekkum DW, Hagenbeek A: Quantitative studies on graft-versus leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia. Bone Marrow Transplant 14:15, 1994
43. Sallusto F, Cella M, Danieli C, Lanzavecchia A: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products. J Exp Med 182:389, 1995
44. Willmer U: Charakterisierung von Makrophagen in Milzen sublethal bestrahlter Mäuse mit Hilfe von monoklonalen Antikörpern. Dipl Arbeit Fak Biologie (Thesis), Ruhr Universität Bochum, June 1981
45. Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S: Effective GvL effects independent of GVHD after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. J Immunol 153:2562, 1994
46. Glass B, Uharek L, Gassman W, Focks B, Bolouri H, Löffler H, Müller-Ruchholtz W: Graft-versus-leukemia activity after bone marrow transplanation does not require graft-versus-host disease. Ann Hematol 64:255, 1992
47. Bortin MM, Renim AA, Saltzstein EC, Rodey GE: Graft versus leukemia. III. Apparent independent antihost and antileukemia activity of transplanted immunocompetent cells. Transplantation 16:182, 1973
48. Mackinnon S, Papadopoulos B, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261, 1995
49. Falkenburg JH, Faber LM, van den Elshout M, van Luxemburg-Heijs SA, Hooftman-den Otter A, Smit WM, Voogt PJ, Willemze R: Generation of donor derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. J Immunother 14:305, 1993
50. Kumar L: Leukemia: Management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 12:1710, 1994